Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.35 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14526699 | 0.99 | TP53 (0.38) | TP53PLA2G4ARORCMCL1BCL2 | |
| SCHEMBL5661557 | 0.85 | TP53 (0.40) | TP53PLA2G4ARORCMCL1BCL2 | |
| SCHEMBL5659447 | 0.85 | TP53 (0.40) | TP53PLA2G4ARORCMCL1BCL2 | |
| SCHEMBL14526519 | 0.84 | TP53 (0.42) | TP53PLA2G4ARORCMCL1BCL2 | |
| SCHEMBL14526514 | 0.83 | TP53 (0.42) | TP53PLA2G4ARORCMCL1BCL2 | |
| SCHEMBL5660891 | 0.83 | PPARA (0.41) | TP53PLA2G4ARORCMCL1BCL2 | |
| SCHEMBL14526723 | 0.82 | TP53 (0.40) | TP53PLA2G4ARORCMCL1BCL2 | |
| SCHEMBL14526521 | 0.81 | TP53 (0.42) | TP53PLA2G4ARORCKMT2AMTNR1A | |
| SCHEMBL14526736 | 0.78 | RORC (0.41) | PLA2G4ARORCMCL1BCL2MTNR1A | |
| SCHEMBL14526671 | 0.76 | LMNA (0.39) | TP53MCL1BCL2KMT2AMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | GPR119, NR1H3, NR1H2 | TP53 4689/4885PLA2G4A 2359/4885RORC 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.